Your Doctor Can Now Prescribe an App for ADHD
New ADHD Stimulant: FDA Decides in 7 Days
The FDA has a deadline. Seven days from now — May 31, 2026 — the agency must act on CTx-1301, Cingulate’s once-daily dexmethylphenidate tablet engineered to deliver three precisely timed doses from a single pill.
This is a stimulant. But it’s not designed like any stimulant currently on shelves.
TL;DR for ADHD Brains
Aspect Details What it is Once-daily dexmethylphenidate with 3 sequentially timed releases FDA decision date May 31, 2026 (PDUFA target action date) Technology Cingulate’s Precision Timed Release™ — 3 cores, each on a separate release clock Phase 3 result Primary endpoint met; statistically significant vs. placebo; no serious adverse events Who it’s for Children and adults with ADHD Availability Pending FDA approval — not yet on the market One-sentence verdict: CTx-1301 is the first stimulant formulation specifically engineered to eliminate coverage gaps, and the FDA answer comes in 7 days.
Best for: People whose current stimulant leaves a midday trough or wears off before the workday ends Skip if: Your current formulation is dialed in with no rebound or coverage gaps
The ADHD Problem CTx-1301 Was Built to Solve
Most people on stimulants know exactly when their medication stops working. Not because they feel better. Because they feel worse.
The afternoon rebound is real: irritability, concentration collapse, the emotional dysregulation that arrives right at homework time or the back half of a work meeting. It’s not a sign something went wrong. It’s what happens when a drug designed to release on a single pharmacokinetic curve runs out of coverage before the day does.
Extended-release formulations helped — a lot. But they don’t fully solve the timing problem. The release curve on most XR formulations rises, peaks, and declines on a single arc. Coverage is longest in the morning, weakest in the afternoon, and typically gone by early evening.
If you’ve ever needed an IR booster at 1pm to get through the back half of the day, you know the gap. And if that second dose has ever kept you awake until midnight, you know why the gap is hard to fill without tradeoffs.
That’s the specific problem CTx-1301 is attempting to solve at the pharmacological level. Not with a new compound, but with a fundamentally different release architecture.
How Precision Timed Release Actually Works
CTx-1301 isn’t a capsule full of beads. It’s a multi-core tablet — three discrete drug-containing cores in a single pill, each surrounded by Cingulate’s proprietary Erosion Barrier Layer (EBL).
The EBL controls when each core releases. Not “extended” in the sense of a slow steady drip. More like a relay race: first core fires at onset, second at a predetermined interval, third later in the afternoon. Each core releases only at its designed time window, with no drug release before the trigger point.
The result: consistent therapeutic plasma levels without the mid-afternoon trough that creates the coverage gap. Rapid onset at the start of the day, maintained coverage through the active hours, and a predictable decline rather than a cliff.
According to Psychiatric Times, the formulation was filed under the FDA’s 505(b)(2) pathway — meaning it references existing data on dexmethylphenidate (the same active ingredient as Focalin) while demonstrating novel clinical benefit through the delivery system. The chemistry isn’t new. The FDA isn’t evaluating an unknown compound. They’re evaluating whether a new delivery mechanism produces clinically meaningful improvements over what already exists.
That narrowed review scope matters. The bar for approval under 505(b)(2) is different from a full novel compound submission.
What Did the CTx-1301 Phase 3 Trials Find?
Short version: positive results, primary endpoints met, no serious adverse events.
Cingulate presented Phase 3 data in October 2025, covering both adult and pediatric populations. What the data showed:
- Primary endpoint met. CTx-1301 produced statistically significant improvement on the ADHD-RS-5 and CGI-S scales versus placebo across pediatric and adult measures.
- Rapid onset observed. Symptom improvement appeared early in the day — consistent with the first-core release mechanism activating as designed.
- Full active-day coverage. Sustained efficacy through up to 12 hours post-dose was the headline clinical claim, and the Phase 3 results supported it.
- Dose-dependent effect. The 37.5 mg dose produced the largest effect size for symptom reduction. Lower doses showed improvement, smaller effect sizes.
- No serious treatment-emergent adverse events. Safety was consistent with the broader stimulant class — expected profile, no unexpected signals.
That’s a solid NDA package. Completed Phase 3 data across age groups, a clear dose-response relationship, and a safety profile built on a compound the FDA already knows well.
None of this guarantees approval. But it’s a more complete clinical file than many drugs that reach a PDUFA date.
Why This Matters If You’re Already on a Stimulant
You might be thinking: why is this relevant if my current medication is working?
The gap problem is more common than prescribers acknowledge. The afternoon trough gets treated as a fixed feature of stimulant therapy — caffeine at 2pm, an IR booster if you have one, or just writing off the 2-5pm window as low-productivity time. If CTx-1301 gets approved, that tradeoff is worth revisiting with your prescriber rather than treating it as a fixed constraint.
Booster dose complexity is a real friction point. If you’re currently on XR plus an IR booster, that’s two separate prescriptions, two separate fills, two separate points of failure in a supply chain that has been unreliable for years. A single tablet that covers the full active day simplifies that considerably.
Formulation choices matter more than most people realize. The science behind how ADHD stimulants work makes this concrete: it’s not just which compound, it’s how that compound is delivered and when. Two people on identical doses of the same active ingredient can have meaningfully different coverage profiles depending on formulation. CTx-1301 doesn’t change the compound. It changes the release architecture. Whether that’s a meaningful clinical upgrade or a pharmacologically clever but practically marginal change is exactly what the Phase 3 data was designed to answer.
Based on those results, Cingulate’s case is reasonably strong.
The Approval Odds Picture
PDUFA dates get treated like results. They’re not.
May 31 is the date the FDA must respond by. That response can go several ways:
Approval. The expected outcome if the clinical file and manufacturing inspection are both in order.
Complete Response Letter (CRL). A rejection with explanation — often requesting additional data, manufacturing changes, or labeling revisions. CRLs don’t kill a drug; they delay it. Sometimes by months, sometimes longer.
Tentative approval. Meets standards but something external (typically a patent dispute) is blocking final clearance.
For CTx-1301, the 505(b)(2) pathway narrows the review surface. The FDA already knows dexmethylphenidate. The clinical question is whether Cingulate’s delivery mechanism adds meaningful benefit over existing formulations, and the Phase 3 data addresses that directly. The safety file doesn’t have surprises.
Compare that to the centanafadine review happening in parallel — a genuinely novel compound with a triple-reuptake mechanism the FDA has no prior reference point for. CTx-1301’s review is structurally simpler. That’s not a guarantee, but it’s a different risk profile.
The most common CRL scenarios — insufficient efficacy data, unexpected safety signals, novel pharmacology questions — are less likely here than for a first-in-class drug.
What Approval Looks Like in Practice
If May 31 brings an approval, don’t expect CTx-1301 on pharmacy shelves in June.
DEA scheduling comes after FDA approval. Dexmethylphenidate is Schedule II. CTx-1301 will almost certainly land there too, which means a separate DEA process before it’s prescribable. Timeline: weeks to a few months after approval.
Insurance coverage lags significantly. New formulations of existing drugs typically face prior authorization requirements when they first enter formularies. Insurers often need evidence that established options were tried and found inadequate. If you want to switch from your current formulation, prepare for that conversation — and have your medication history organized. It saves weeks of back-and-forth.
Pricing is unknown. Cingulate hasn’t announced launch pricing. Novel delivery systems for existing compounds often launch at premium prices without generic competition. The ADHD medication shortage created a market that’s unusually sensitive to access and cost, and a Schedule II drug with premium pricing could face real adoption headwinds even after approval.
Dosage optimization still applies. The Lancet’s dosage meta-analysis from earlier this month made clear that the right drug at the wrong dose is still subtherapeutic treatment. CTx-1301 is no different. If it gets approved and you switch, plan to work with your prescriber to find the right dose — the Phase 3 data showed meaningful differences between dose levels, and the optimal dose for you isn’t necessarily the one with the largest average effect size.
How to Prepare Before May 31
The next seven days are worth using, whether CTx-1301 gets approved or not.
Document your current coverage pattern. Track when your medication kicks in, when it starts to fade, and when you’re clearly out of coverage. Specific observations — “I lose focus around 2pm every day,” “I’m irritable by 4pm on workdays” — are the data your prescriber needs to evaluate whether a formulation change makes sense. Vague reports of “it’s not working great” don’t move the clinical conversation.
(One more thing: put June 1 in your calendar — in three places. The FDA’s response may drop on the 31st or just after, and this is exactly the kind of update that disappears in a notification pile if you’re not specifically watching. Best pill reminder apps aren’t just for doses — those calendar alerts actually surface when other reminders don’t.)
Start the conversation with your prescriber now. Don’t wait for approval to mention CTx-1301. A prescriber who knows the drug is on your radar will move faster once it becomes prescribable than one learning about it from you for the first time after approval. A sentence at your next appointment is enough: “I’ve been following CTx-1301 — I have an afternoon coverage issue that might be relevant.”
The Bottom Line
CTx-1301 isn’t a new compound. It’s dexmethylphenidate — the same active ingredient in Focalin — delivered through a mechanism designed to replicate what three separate doses would do, without requiring three separate doses.
If it works as designed and gets approved, the practical upside is real: fewer prescriptions to manage, more predictable coverage, and potentially eliminating the afternoon gap that most XR users have accepted as an unavoidable feature of their treatment.
The FDA has until May 31. The Phase 3 data is solid. The approval pathway is more contained than a novel compound review.
Check back June 1.
Never adjust your medication without talking to your prescriber. Approval timelines can shift. This post reflects publicly available information as of May 24, 2026.
